● MaxCyte has built aBusinessmost investors never see directly: it supplies the cell-engineering technology that helps biotech companies develop cell and gene therapies.
Myriad Genetics has become one of 2026's more closely tracked diagnostics turnaround stories, and not for flattering reasons. After a steep share-price decline and a wave of analyst downgrades, the molecular-diagnostics veteran enters the autumn trading near multi-year lows, with investors focused squarely on …
● Based in Danbury, Connecticut, MannKind develops treatments for endocrine and orphan lung diseases built on its proprietary Technosphere dry-powder inhalation platform.
● Modular Medical develops the Pivot tubeless insulin patch pump, a wearable system that delivers continuous basal and bolus insulin over a three-day wear period, with a removable reservoir, a disposable battery and smartphone connectivity.
Medtronic plc (NYSE:MDT) heads into the back half of 2026 looking less like a name in transition and more like one quietly regaining its footing. A raised fiscal 2027 outlook, delivered alongside a roughly $700 million robotics partnership, gave investors two fresh reasons to …
● MediWound has spent 2026 building a quietly compelling case as a specialist in tissue repair and wound care, and its Nasdaq-listed shares reflect that trajectory near $14 with a marketCapitalizationaround $180 million.
A commercial-stage diagnostics company can post double-digit revenue growth and still find its shares under a dollar, a tension that defines MDxHealth SA (NASDAQ: MDXH) heading into autumn 2026. The Nasdaq-listed molecular diagnostics group has built a growing prostate-cancer testing franchise, yet a sliding …
Few small-cap health-tech stories have shifted direction as sharply as Mangoceuticals, Inc. (NASDAQ: MGRX), the telemedicine company now attempting to reinvent itself through a proposed pivot into nuclear technology. As September 2026 unfolds, the Nasdaq-listed men's-health platform is juggling a looming listing-compliance deadline, a …
Manhattan Scientifics, Inc (OTC:MHTX) is the kind of long-lived, technology-focused micro-cap that periodically resurfaces in speculative trading chatter, and the ticker has drawn renewed attention after a sharp move. The framing warrants an important caveat up front: in an over-the-counter name quoted at a …
Meihua International Medical Technologies (OTC:MHUAF) is a name that now sits well off the radar of most U.S. investors, and for good reason. The China-based medical-device manufacturer was pushed off the Nasdaq in late 2025 and now changes hands in the over-the-counter market, where …